UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2016-03, Vol.17 (3), p.367-377

2016

Volltextzugriff (PDF)

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-07, Vol.14 (1), p.4444-4444, Article 4444

2023

Volltextzugriff (PDF)

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-08, Vol.14 (1), p.4741-4741, Article 4741

2023

Volltextzugriff (PDF)

Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6674-6681

2005

Volltextzugriff (PDF)

Autocrine Metabolism of Vitamin D in Normal and Malignant Breast Tissue

Clinical cancer research, 2005-05, Vol.11 (9), p.3579-3586

2005

Volltextzugriff (PDF)

Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population

European journal of cancer (1990), 2005-05, Vol.41 (8), p.1164-1169

2005

Volltextzugriff (PDF)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Breast cancer research : BCR, 2019-03, Vol.21 (1), p.39-39, Article 39

2019

Volltextzugriff (PDF)

Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1336-1343

2001

Volltextzugriff (PDF)

Vitamin D Receptor Gene Polymorphisms and Breast Cancer Risk

Clinical cancer research, 2004-08, Vol.10 (16), p.5472-5481

2004

Volltextzugriff (PDF)

Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study

Journal of clinical oncology, 2005-05, Vol.23 (13), p.2988-2995

2005

Volltextzugriff (PDF)

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer

The New England journal of medicine, 2006-11, Vol.355 (18), p.1851-1862

2006

Volltextzugriff (PDF)

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

The lancet oncology, 2005-06, Vol.6 (6), p.383-391

2005

Volltextzugriff (PDF)

Vitamin D Status and Breast Cancer Risk

Anticancer research, 2006-07, Vol.26 (4A), p.2573-2580

2006

Volltextzugriff (PDF)

Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study

The Lancet (British edition), 1999-07, Vol.354 (9174), p.197-202

1999

Volltextzugriff (PDF)

100 Cancer Research UK (CRUK) National Standardised Regimen-Specific Non-Small Cell Lung Cancer (NSCLC) Consent Forms for Systemic Anti-Cancer Therapies (SACT): Where Are We Now?

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107661, Article 107661

2024

Volltextzugriff (PDF)

Altered Nuclear Receptor Corepressor Expression Attenuates Vitamin D Receptor Signaling in Breast Cancer Cells

Clinical cancer research, 2006-04, Vol.12 (7), p.2004-2013

2006

Volltextzugriff (PDF)

The impact of GOLD (Geriatric Oncology Liaison Development) service in oncology patients with significant co-morbidities and/or borderline performance status

Journal of clinical oncology, 2019-11, Vol.37 (31_suppl), p.90-90

2019

Volltextzugriff (PDF)

61 - Use of Cancer Research UK (CRUK) national standardised regimen specific lung consent forms for systemic anti-cancer therapies (SACT)

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.S28-S29

2022

Volltextzugriff (PDF)

Use of Cancer Research UK (CRUK) national standardised regimen specific lung consent forms for systemic anti-cancer therapies (SACT)

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.S28-S29

2022

Volltextzugriff (PDF)

Electronic frailty index predicts 30-day mortality from chemotherapy in breast, colorectal and lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.12009-12009

2023

Volltextzugriff (PDF)

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1688-1700

2017

Volltextzugriff (PDF)

Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy

Radiology, 2014-07, Vol.272 (1), p.100-112

2014

Volltextzugriff (PDF)

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

The Lancet (British edition), 2019-06, Vol.393 (10191), p.2599-2612

2019

Volltextzugriff (PDF)

The Expression of ERβcx in Human Breast Cancer and the Relationship to Endocrine Therapy and Survival

Clinical cancer research, 2004-04, Vol.10 (7), p.2421-2428

2004

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(85)
Buchkapitel
(1)

Sprache

Englisch
(86)

Erscheinungsjahr

n.n

Thema

Humans
(53)
Science & Technology
(52)
Life Sciences & Biomedicine
(51)
Female
(46)
Oncology
(38)
Middle Aged
(33)
Adult
(32)
Biological And Medical Sciences
(30)
Medical Sciences
(30)
Aged
(24)
Breast Cancer
(24)
Tumors
(24)
Breast Neoplasms - Drug Therapy
(18)
Chemotherapy
(16)
Breast Neoplasms - Pathology
(14)
Treatment Outcome
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Gynecology. Andrology. Obstetrics
(13)
Cancer Therapies
(12)
Patients
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

Autocrine Metabolism of Vitamin D in Normal and Malignant Breast Tissue

Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population

Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin

Vitamin D Receptor Gene Polymorphisms and Breast Cancer Risk

Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

Vitamin D Status and Breast Cancer Risk

Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study

100 Cancer Research UK (CRUK) National Standardised Regimen-Specific Non-Small Cell Lung Cancer (NSCLC) Consent Forms for Systemic Anti-Cancer Therapies (SACT): Where Are We Now?

Altered Nuclear Receptor Corepressor Expression Attenuates Vitamin D Receptor Signaling in Breast Cancer Cells

The impact of GOLD (Geriatric Oncology Liaison Development) service in oncology patients with significant co-morbidities and/or borderline performance status

61 - Use of Cancer Research UK (CRUK) national standardised regimen specific lung consent forms for systemic anti-cancer therapies (SACT)

Use of Cancer Research UK (CRUK) national standardised regimen specific lung consent forms for systemic anti-cancer therapies (SACT)

Electronic frailty index predicts 30-day mortality from chemotherapy in breast, colorectal and lung cancer

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

The Expression of ERβcx in Human Breast Cancer and the Relationship to Endocrine Therapy and Survival

Suchergebnisse filtern